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Lactococcus lac/is is a non-pathogenic and non-colonising bacterium, which is being 
developed as a vaccine delivery vehicle for immunisation by mucosal routes. To 
determine whether lactococci can express the Chicken Anaemia Virus capsid protein 
(VPI )  in immunogenic fonn, we have constructed a recombinant DNA, which 
constitutively expresses the VPI as N-tenninal fusion protein with Open Reading 
Frame-32 under the control of lactococci promoter P32 in vector pMG36e. 
Chicken anaemia virus (CAV) is a member of the newly categorised Circoviridae, a 
family of circular negative single-stranded DNA viruses. CAY VPI gene ( 1 .4 kb) 
was amplified by PCR from CA V genome which was isolated from infected Marek's 
disease virus transfonned lymphoblastoid cell line (MDCC-MSB 1 )  cell lysate and 
cloned into pCR®2 . I -TOPO vector for sequencing. The sequenced VPI gene, 
lacking its own promoter, was cloned into the lactococcal expression vector 
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pMG36e and transformed into E. coli JM1 09 as the intermediate host. The 
recombinant plasmid was sub-cloned into L. lactis MG 1 363 by electroporation. 
Several independent verifying methods such as sequencing, Southern hybridisation 
and restriction enzymes analysis have confirmed the insertion of VPl gene into 
pMG36e. The complete sequence of VPI gene has 99.65% homology compared to 
the published CA V Cux-l VPl gene. A total of 5 base difference was seen to result 
in change of 3 amino acids sequence in the polypeptide chain. The expression of 
fusion protein was studied until transcriptional level . Transcription of fusion gene 
from strains of recombinant L. lactis MG 1363 were analysed by Northern 
hybridisation. Northern hybridisation has detected transcription of fusion gene in 
recombinant L. iactis MG1363 carrying pMG36e-VPl and produced mRNA with the 
size of 1.4 kb. 
On the basis of these results, it is concluded that the recombinant DNA pMG36e was 
successfully constructed in bacteria E. coli JM1 09 and subcloned into L. lactis 
MG1363. The recombinant DNA in L. lactis MG1 363 is capable to express the 
fusion protein up to transcriptional level. Therefore, recombinant L. lactis MG 1 363 
can be used as a potential vaccine delivery system against CA V infections. 
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sebagai memenuhi keperluan untuk ijazah Master Sains. 
PENGKLONAN GEN VPl VIRUS ANAEMIA A YAM (CUX-l) KE DALAM 
SATUVEKTOR PENGEKPRESLACTOCOCCUSpMG3� 
Oleh 
NG PERK TSONG 
Ogos 1999 
Pengerusi: Raha Abdul Rahim, Ph.D. 
Fakulti: Sains Makanan dan Bioteknologi 
LaclococcuS lactis ialah sejenis bacteria yang bukan patogenik dan tidak 
mengkoloni yang telah direka sebagai agen untuk pengangkutan vaksin untuk tujuan 
immunisasi melalui kaedah mucosal. DNA rekombinan yang mengekspres VPI 
sebagai terminal N protein fusion dengan Open Reading Frame-32 di bawah 
pengawalan promoter P32 di dalam vektor pMG36e telah dibina untuk menentukan 
sarna ada lactococci boleh mengekspres protein kapsid (VPI ) yang immunogenik. 
Virus anemia ayam (CAV) adalah ahli kepada keluarga baru yang dinamakan 
Circoviridae, iaitu kumpulan yang mempunyai DNA bulatan negatif satu rantai . 
Gen VPI ( 1 .4 kb) telah diamplifikasikan melalui PCR daripada genom CAY yang 
diekstrak dari sel MDCC-MSB I yang telah dijangkiti oleh CA V dan diklonkan ke 
dalam vektor pCR®2. l -TOPO untuk penentuan jujukan DNA. Gen VPI tanpa 
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promoter telah dimasukkan ke dalam vektor pengekpres pMG36e dan ditransfom ke 
dalam E. coli JM109 sebagai perumah perantara. DNA recombinan ini kemudian 
dipindahkan ke dalam bakteria L. lactis MG 1 363 dengan kaedah electroporation. 
Beberapa kaedah pengesahan termasuk penentuan jujukan DNA, analisis dengan 
enzim pembatas dan penghibridan Southern telah menunjukkan bahawa gen VPl 
telah berjaya dimasukkan ke dalam vektor pMG36e. Keseluruhan penentuan jujukan 
DNA menunjukkan gen VPl mempunyai homologi 99.65% berbanding dengan 
jujukan DNA gen VPl CAY Cux-l yang telah diterbit. Sejumlah 5 perbezaan bes 
dalam jujukan DNA telah membawa perubahan kepada 3 jujukan asid amino di 
dalam rantai polipeptida. Kajian terhadap pengekspresan protein fusion telah 
mencapai ke tahap transkripsi. Transkripsi gen fusion daripada strain L. lactis 
MG1363 rekombinan telah dianalisis dengan penghibridan Northern. Penghibridan 
Northern menunjukkan bahawa transkripsi gen fusion telah belaku di dalam strain L. 
lactis MG1 363 yang mengandungi pMG36e-VPl dan menghasilkan mRNA bersaiz 
1 .4 kb. 
Berdasarkan hasil kajian yang diperolehi, ia boleh disimpulkan bahawa DNA 
rekombinan telah berjaya dibina dalam bakteria E. coli JMI09 and disubklon ke 
dalam L. iactis MG1 363. DNA rekombinan di dalam L. lac/is MG1 363 berupaya 
mengekspres protein fusion sehingga tahap transkripsi. Oleh itu, L. lactis MG 1 363 
rekombinan berpotensi untuk digunakan sebagai sistem pengangkutan vaksin bagi 
mencegah jangkitan CA V. 
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Chicken anaemia virus (CA V) is a member of the newly categorised family 
Circoviridae. CA V is a small icosahedral shaped DNA virus. The virus causes a 
syndrome in chicken characterised by aplastic anaemia, lymphoid depletion, 
subcutaneous and intramuscular haemorrhages and increased mortality (Yuasa et 
ai. , 1979). It also causes the destruction of the erythroblastoid cells in bone 
marrow and depletion of cortical CD4+ lymphocytes in the thymus, resulting in 
acute anaemia and immunodeficiency (Jeurissen et ai. , 1989). 
Current vaccines for CA V are based on either live attenuated or inactivated CA V 
(Steenhuisen et aI. , 1994); however, there are drawbacks in each approach. The 
use of attenuated viral vaccines carries the risk that the virus is not truly 
attenuated. Consequently, the chickens may become infected by CA V. Such 
infections are often asymptomatic and result in lower growth and weight gain 
rates. 
Several researchers have studied cloning and sequencing of genomic DNA from 
CAY (Claessens et aI. , 1991; Noteborn et aI. , 1991; Meehan et aI. , 1992). Gene 
sequences have been isolated that could be used to make a subunit vaccine 
against CA V. Amplified CA V genes were cloned into plasmids and transformed 
to suitable host such as bacteria and baculovirus (pallister, 1994; Kato et al. , 
1995; Koch et aI. , 1995). The expression of the cloned gene(s) was determined 
by screening of the fusion protein. Since subunit vaccines utilise recombinantly 
expressed proteins of the virus and not the virus itself, the problem of infections 
inherent in the use of attenuated viruses as vaccines can be overcomed. 
Furthermore, manufacture of recombinant proteins for use as subunit vaccines are 
less expensive than the culture and inactivation of the viruses used in inactivated 
viral vaccines. 
Lactococcus is one of the important groups of lactic acid bacteria. It is a Gram­
positive cocci and produces lactic acid during fermentation process. Lactococcus 
consists of two major subspecies: L. lactis subsp. lactis and L. lactis subsp. 
cremoris. This bacterium has importance for major economic activities, 
primarily their use in a variety of dairy fermentation such as cheese production. 
Much effort has been put into the development of methods to modify these 
microorganisms genetically. Transformation systems were developed and 
special-purpose cloning vectors became available (Kok , 1991). 
Increasing knowledge of the molecular biology of the lactic acid bacteria creates 
the interest in the development of alternative bacterial vaccine vectors based on 
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the harmless and non-pathogenic bacteria as cloning and antigen vehicles. Such a 
system would be particularly suited for mucosal immunisation of geriatric and 
paediatric populations. In contrast to conventional vaccines, which are largely 
derived from attenuated pathogens such as Salmonella and BCG (Dougan et al. , 
1993; Stover et al. , 1993), the lactic acid bacteria are generally regarded as safe 
organisms making them particularly attractive for use as antigen delivery 
vehicles. L. lactis was able to produce high levels of heterogeneous antigen 
expression in vitro prior to inoculation of the bacteria (Norton et al. , 1995). 
Therefore this system does not require in vivo expression of the antigen in the 
host. Furthermore L. lactis has a low innate immunogenicity and it is possible to 
carry out sequential oral inoculations of this bacterium without inducing a 
significant increase in the antibacterial antibody response, thus reducing the risk 
of interference from antibacterial antibodies (Norton et al. , 1995). 
Objectives 
The objective of this study is to clone the VP l  gene of the CAY Cux-l strain into 
the lactococcal expression vector pMG36e. The VPI gene is first amplified by 
the polymerase chain reaction and then cloned into the pCR®2.1 cloning vector 
for product verification. The VPI gene is then subcloned in-frame with ORF-32 
into pMG36e and transformed into L. lactis MG1363. The fusion gene 




Chicken Anaemia Virus (CA V) 
Introduction 
CA V is a member of the newly categorised Circoviridae, a family of circular 
negative single-stranded DNA viruses that also includes the porcine circovirus 
and the beak and feather disease virus of parrots (Studdert, 1993). These 
viruses are grouped together on the basis of a common geliome form, but there 
were no similarity in amino acid composition, open reading frame (ORF) 
arrangement, nor transcriptional machinery have been identified. The virion is 
a sma)), icosahedral DNA virus with an average diameter of 25 nm (Goryo el 
al. , 1987). It is resistant to treatments with chloroform, ether, pH 3, heating at 
80°C for 5 min and can be cultured in Marek's disease virus transformed 
chicken lymphoblastoid cell line (MDCC-MSB 1 ). 
PERPUSTAKAAN 
JNIVERSITI PUfRA MALAY§1A 
CAY was first isolated from chicken in Japan by Yuasa et al. (1979). Since then 
it has been detected and isolated in other part of the world such as Gennany 
(von Bulow et aI. , 1983; Vielitz and Landgraf, 1988), Sweden 
(Engstrom, 1988), United Kingdom (Chettle et aI. , 1989; McNulty et al., 1989), 
the USA (Goodwin et aI. , 1989; McNulty et al., 1989; Rosenberger and Cloud, 
1989; Lucio et al., 1990), Australia (Firth and Imai, 1990), and China (Zhou et 
af., 1997). However, only one serotype of CAY has been found, so far and 
these were all pathogenic for young chickens. 
In Malaysia, preliminary study to detennine the presence of CA V in flocks of 
commercial chicken was done by Rozanah et af. (1 995). A total of 322 serum 
samples were randomly collected from layers, broilers and parent stock of 
different ages from 13 farms in 3 states of Malaysia (Selangor, Negeri Sembi Ian 
and Johor) and tested with enzyme-link immunosorbant assay (ELISA) kit using 
CA V hyperimmune antiserum. Liver and spleen of CA V antibody positive 
chicken were further tested for the presence of CA V antigen by indirect 
immunofluorescent and immunoperoxidase staining. The results showed that 
CAY antibody could be detected in 218 (61.4%) sera out of 355 sera tested. 
The antibodies were detected in all age groups of chicken from one day old to 
70 weeks old including layers, broiler and parent stock flocks. Antigen of CA V 
was detected in the nuclei and cytoplasm of hepatocytes from 2 antibody 
positive chickens. The nuclei of the hepatocytes were stained intensely while 
the cytoplasm was lightly stained. This finding confinned that Malaysian 
chicken flocks are not free from CA V and the infection is highly prevalent. 
Genomic Organisation and Gene Products of CAV (Cux-I) 
The CA V Cux-l strain genome was first reported to be composed of a single­
stranded circular DNA molecule of 2319 nucleotides (Noteborn et aI. , 1991). 
However, the genome size of most naturally occurring isolates including Cux-l 
was reported to be 2298 bases because of the lack of one copy unit of the 21-
base tandem repeat located on the non-coding region on the genome (Claessens 
et al. , 1991; Meehan et al. , 1992). 
A study on CAY transcription by Notebom et al. (1992) showed that the major 
transcript from the CA V genome is an unspliced messenger (mRNA) of about 
2100 nucleotides. Its transcription start point and poly(A)-addition site are 
located at nucleotides 354 and 2317 of the CA V sequence, respectively. In vitro 
translation experiments provide evidence that the major CA V open reading 
frame encodes a 52 kDa protein by using the fifth AUG as a start codon of the 
unspliced CAY mRNA. This 2.0 kb transcription product was further 
confirmed by Phenix el al. (1994) by using strand-specific riboprobes 
representative of either strand of the chicken anaemia virus replicative form 
(RF) DNA. The results indicated that only one strand of the RF was transcribed 
to produce a major 2.0 kb transcript and it shown that the :;:ncapsidated DNA 
was of negative sense, which was not transcribed. Primer extension analysis 
located a single transcriptional start site at nucleotide position 360 bp (Figure 1) 
of the CA V sequence (Phenix el al. 1994). Northern blot analysis using a series 
of genomic probes indicated that the 2. 0 kb transcript was devoid of splicing 
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and identified a non-transcribed region of the genome. Both studies showed 
that only plus strand of CA V DNA transcribed and VP1 gene transcription 
started at the firth AUG of the unspliced mRNA as start codon. 
The non-transcribed region of the CA V DNA located upstream of the three 
major ORFs (position 2207-385 bp, Figure 1)) encompasses a region high in 
GC content, a poly(A) signal and four copies of an 18 repeat element. The non­
transcribed region was shown to possess promoter activity, enhancing the 
expreSSIOn of human growth hormone reporter gene in a transient gene 
expression assay (Phenix et a/. 1994). This region contains sequences 
considered to have roles in the initiation and regulation of transcription 
(Claessens et a/. , 1991; Notebom et a/., 1991; Meehan et aI. , 1992). The 
promoter region, 'T AT A box' (position 329-336) is believed to be the RNA 
polymerase II transcription factor binding sequence element. The 'T A T A box' 
is found 50 nucleotides upstream of the initiation codon of the VP2 ORF. The 
promoter enhancer region of CA V contains four direct repeats, which are 
unique for CA V DNA. Each repeat contains a sequence that was homologous 
to the one that binds the adenovirus transcription factor (ATF) site. Lee at a/. 
(1987) reported that some ATF sites are activated by the E1A protein of 
adenovirus. Moreover, in dual infection of chickens, adenovirus is enhanced by 
CAY, as is shown by higher virus titres (von Bulow et a/., 1986). 
The CA V Cux-l 2319 bp DNA (Figure 1) contained all the genetic infonnation 
needed for the complete replication cycle of CAY. Notebom et a/. (1991) 
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